NL-OMON37015Not yet recruitingNot Applicable
Effects of orally administered Beta-Glucan on leukocyte function in humans, a pilot study - Effects of oral Beta-Glucan on human leukocytes
niversitair Medisch Centrum Sint Radboud0 sites15 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 15
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •- Written informed consent;
- •- Age >=18;
- •- Healthy male;
Exclusion Criteria
- •- Subjects with a history of allergy or intolerance to Beta-glucan;
- •- Use of any medication;
- •- Participation in a drug trial or donation of blood 3 months prior to Beta-glucan administration;
- •- Use of antibiotics, norit, laxatives (up till 6 months prior to inclusion), cholestyramine, acid burn inhibitors or immune suppressive agents (up till 3 months prior to inclusion), and pre- and probiotics (up till 1 month prior to inclusion).
Investigators
Similar Trials
Completed
Not Applicable
Effects of Orally Administered Beta-glucan on Leukocyte Function in HumansImmunologic Deficiency SyndromesNCT01727895Radboud University Medical Center15
Completed
Not Applicable
The effect of Beta Glucan and both of Beta Glucan and Lactobacillus Rhamnosus GG on immune system , nutritional status and side effects of chemptherapy in breast cancer patientsBreast Cancer.Malignant Neoplasm of BreastIRCT201212172017N10Hematology Oncology Research Center, Tabbriz University of medical Sciences45
Completed
Phase 1
Effectiveness of beta-glucan supplementation to interleukine-6, interleukine-10 and tumour necrosis factor alpha in overweight and obese subjectInflammationInterleukinTumour nacrosis factorTCTR20140604001Core Chematis Co., Ltd44
Not yet recruiting
Unknown
Clinical evaluation study of Beta-glucan assayinvasive fungal infectionsJPRN-UMIN000050121Osaka Metropolitan University900
Completed
Phase 3
Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot UlcersChronic Diabetic Foot UlcersNCT00632008Biotec Pharmacon ASA122